COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression.

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression.

Florence Carrouel, Maria Pia Conte, Julian Fisher, Lucio Souza Gonçalves, Claude Dussart, Juan Carlos Llodra, Denis Bourgeois

Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS‐CoV‐2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS‐CoV‐2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS‐CoV‐2, the use of a mouth rinses and/or with local nasal applications that contain β-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS‐CoV‐2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of βCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression.

2020

COVID-19, 2019ncov, SARS-CoV-2, Oral cavity, mouthrinse, β-cyclodextrins

DOI: 10.3390/jcm9041126

Journal of Clinical Medicine

MDPI AG

Medicine

EN